Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer | Zendy

Guanghui Gao | Zendy; Meng Qiao | Zendy; Hongcheng Liu | Zendy; Tao Jiang | Zendy; Fei Zhou | Zendy; Xuefei Li | Zendy; Chao Zhao | Zendy; Xiaoxia Chen | Zendy; Chunxia Su | Zendy; Shengxiang Ren | Zendy; Caicun Zhou | Zendy

Open Access

Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer

Author(s) -

Guanghui Gao,

Meng Qiao,

Hongcheng Liu,

Tao Jiang,

Fei Zhou,

Xuefei Li,

Chao Zhao,

Xiaoxia Chen,

Chunxia Su,

Shengxiang Ren,

Caicun Zhou

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.09.19

Subject(s) - medicine , hazard ratio , lung cancer , confidence interval , cochrane library , meta analysis , oncology , gastroenterology , randomized controlled trial , clinical trial , subgroup analysis , population , combination therapy , environmental health

To investigate the impact of different immune checkpoint inhibitors (ICI), programmed-death ligand 1 (PD-L1) expression and clinical characteristics on clinical outcome of ICI plus conventional treatment in advanced lung cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research